أطروحة الماجستير للطالبة إيناس مخيمر من قسم الصيدلة السريرية

ناقشت بنجاح طالبة الماجستير إيناس مخيمر من قسم الصيدلة السريرية اليوم الخميس الموافق 3/11/2016م أطروحة الماجستير بعنوان:

دراسة التأثير الوقائي (للإيتازوليت) ضد الاختلال  في الحركة، التعلّم والذاكرة  والاكتئاب،  المصاحب لمرض الرعاش

ETAZOLATE NEUROPROTECTIVE EFFECTS IN A RAT MODEL OF PARKINSON'S DISEASE INDUCED BY 6-HYDROXYDOPAMINE

وقد ضمت لجنة المناقشة الأستاذ الدكتور كارم الزعبي رئيساً وعضوية كل من الدكتور أمجد أبو رميلة والدكتور محمد القضاة والأستاذة الدكتورة عبلة بصول كممتحن خارجي. باسم صفحة أصدقاء كلية الصيدلة_ في جامعة العلوم والتكنولوجيا الأردنية نبارك للطالبة إيناس مخيمر إتمامها درجة الماجستير في الصيدلة السريرية بنجاح وتفوق متمنين لها مزيدا من التقدم.

للإطلاع على ملخص الدراسة

Background: Parkinson’s disease is an incurable and debilitating neurodegenerative disease that is characterized by degeneration of dopaminergic neurons. Etazolate is a pyrazolopyridine compound that selectively modulates the GABA (A) receptor through inhibition of adenosine receptors. Moreover, it selectively inhibits phosphodiesterase IV which is suggested to increase the cAMP availability and promotes cAMP/CREB/BDNF signaling which in turn mediates neuronal survival and plasticity. Therefore, it has a potential beneficial effect in controlling PD pathogenesis.

Aim: To evaluate etazolate treatment on defective motor performance, depressive – like behavior and cognitive impairment related to PD. 

Method:  PD was induced in rats by injecting 6-OHDA in the right medial forebrain bundle (MFB). Apomorphine induced rotation test was used to behaviorally evaluate 6-OHDA induced motor deficits, tail suspension was conducted as behavioral tests of  depression-like symptoms, while radial arms water maze was used to evaluate cognitive function. Etazolate was administered orally at a dose of 1mg/kg/day for 14 days after 7 days of the stereotaxic surgical procedure and its effect was compared to other control group. Finally, the hippocampus was dissected; antioxidant markers and BDNF protein level were assessed by Enzyme-Linked Immunosorbent Assay (ELISA).

Findings: Etazolate administration significantly improves the 6-OHDA induced PD related symptoms including motor deficits, depression and impairment in both short and long term memory. Moreover, our findings show that etazolate significantly normalizes oxidative stress related parameters (GSH, GSSG, GPx) and BDNF levels.

Conclusion: Motor dysfunction, depressive- like behavior, and memory deficits in the 6-OHDA rat model of Parkinson’s can be significantly improved with etazolate. This impairment could be through enhancing antioxidants capacity and BDNF level in 6-OHDA lesioned animal.